Sofia Hakansson Buch

Vice President for Cell Therapy CMC • Novo Nordisk

Sofia leads the Cell Therapy CMC unit, in Måløv, Denmark, being responsible for analytical, formulation and process development. She has been driving the establishment of a cell therapy in-house manufacturing site in California and is also the link between Novo Nordisk R&D and Product Supply for the cell therapy portfolio. Sofia is a member of the Novo Nordisk cell therapy governance board and of several joint steering committees with external partners. In total, Sofia has worked 16 years at Novo Nordisk in various positions such as research scientist in the Protein Chemistry unit, Diabetes Research Unit, as line manager within recombinant technologies (heading up the mammalian and yeast platforms in Global Research) and as project leader for different projects (both therapeutic and technology projects). Sofia´s basic education is a MSc in Chemistry and a PhD in Molecular Biotechnology. 

Also speaking

Jenny Prange

CSO and Co-Founder • Muvon Therapeutics

Michael von Forstner

Global Head of Clinical Safety and Pharmacovigilance • Biogen

Karin Blumer

Director Global Patient Engagement • Novartis

Event Info


Sponsorship Brochure

Take a look at the 2023 sponsorship opportunities here.

Agenda at a Glance

Check out the Agenda at a Glance for Advanced Therapies Europe 2023.